Drug & intervention
exemestane
RxCUI 258494
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Background context
Exemestane
Exemestane, sold under the brand name Aromasin among others, is a medication used to treat breast cancer. It is a member of the class of antiestrogens known as aromatase inhibitors. Some breast cancers require estrogen to grow. Those cancers have estrogen receptors (ERs), and are called ER-positive. They may also be called estrogen-responsive, hormonally-responsive, or hormone-receptor-positive. Aromatase is an enzyme that synthesizes estrogen. Aromatase inhibitors block the synthesis of estrogen. This lowers the estrogen level, and slows the growth of cancers.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Clinical trials
40 shownTesting Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNCT07391774 · 2026-08-10
RECRUITINGA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22
RECRUITINGA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.NCT07062965 · 2025-08-05
RECRUITINGA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27
RECRUITINGSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01
RECRUITINGFunctional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerNCT06179303 · 2024-07-22
RECRUITINGPhase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28
RECRUITINGDCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentNCT06075953 · 2024-02-17
RECRUITINGEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)NCT05891093 · 2023-06-01
RECRUITINGFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · 2023-04-17
RECRUITINGA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31
RECRUITINGPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerNCT05573126 · 2023-01-11
RECRUITINGRibociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerNCT05467891 · 2022-09-13
RECRUITINGA Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · 2022-03-30
RECRUITINGEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreNCT02476786 · 2017-01-17
RECRUITINGRandomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNCT07499999 · 2026-09-09
NOT_YET_RECRUITINGA Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerNCT06630325 · 2025-06-24
TERMINATEDOptimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNCT06223698 · 2025-05-02
NOT_YET_RECRUITINGTesting Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19
SUSPENDEDStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)NCT06428396 · 2024-11-27
ACTIVE_NOT_RECRUITINGSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyNCT06957379 · 2024-02-29
ACTIVE_NOT_RECRUITINGA Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentNCT06105632 · 2024-01-09
ACTIVE_NOT_RECRUITINGOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16
ACTIVE_NOT_RECRUITINGTRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerNCT06001762 · 2023-10-05
ACTIVE_NOT_RECRUITINGAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05
ACTIVE_NOT_RECRUITINGA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04
ACTIVE_NOT_RECRUITINGA Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)NCT05306340 · 2022-08-03
ACTIVE_NOT_RECRUITINGEfficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 · 2021-10-12
TERMINATEDA Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04
ACTIVE_NOT_RECRUITINGAnalysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.NCT04852081 · 2021-01-01
UNKNOWNStudy to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsNCT04300790 · 2020-10-23
COMPLETEDA Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast CancerNCT04572295 · 2020-10-09
COMPLETEDNeoadjuvant Tucidinostat and Exemestane in Early Breast CancerNCT04465097 · 2020-07-08
COMPLETEDEffect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the BreastNCT04666805 · 2020-07-01
UNKNOWNT-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerNCT03554044 · 2020-02-05
COMPLETEDPhase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerNCT04059484 · 2019-10-22
TERMINATEDPalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast CancerNCT02917005 · 2019-05-07
UNKNOWNThe Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast CancerNCT04129216 · 2019-02-20
COMPLETEDRadiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisNCT03691493 · 2019-02-08
COMPLETEDBreast Cancer Treatment Based on Organ-like CultureNCT03925233 · 2019-01-02
UNKNOWNConditions being studied
Breast Cancer77Breast Neoplasms26Metastatic Breast Cancer18Advanced Breast Cancer6Anatomic Stage IV Breast Cancer AJCC v86HER2/Neu Negative6Anatomic Stage III Breast Cancer AJCC v85Stage IV Breast Cancer5Estrogen Receptor Positive4Recurrent Breast Carcinoma4ER+ Breast Cancer3Estrogen Receptor Positive Breast Cancer3Estrogen Receptor-Positive Breast Cancer3HER2-negative Breast Cancer3Human Epidermal Growth Factor 2 Negative Carcinoma of Breast3Invasive Breast Carcinoma3Recurrent Breast Cancer3Stage II Breast Cancer3Stage IIIA Breast Cancer3Stage IIIC Breast Cancer3
Research locations
HoustonTexas, United States37New YorkNew York, United States37BostonMassachusetts, United States36NashvilleTennessee, United States35ChicagoIllinois, United States30Los AngelesCalifornia, United States27MadridSpain26St LouisMissouri, United States25DallasTexas, United States24BarcelonaSpain23MinneapolisMinnesota, United States23BaltimoreMaryland, United States22
Leading sponsors
Pfizer15Novartis Pharmaceuticals12AstraZeneca6Eli Lilly and Company6National Cancer Institute (NCI)6ETOP IBCSG Partners Foundation4University of Washington4Dana-Farber Cancer Institute3Mayo Clinic3Merck Sharp & Dohme LLC3NCIC Clinical Trials Group3Roxane Laboratories3Spanish Breast Cancer Research Group3Syndax Pharmaceuticals3Alliance for Clinical Trials in Oncology2
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.